PMID- 34900792
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220811
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 20
IP  - 2
DP  - 2021 Dec
TI  - Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes 
      mellitus patients.
PG  - 1407-1413
LID - 10.1007/s40200-021-00874-4 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a metabolic disorder in which the 
      patients with high blood sugar develop insufficient insulin secretion or insulin 
      resistance. The solute carrier family, 5 member 2 (SLC5A2) gene is a member of 
      sodium/glucose transporter family which can reduce heart and kidney problems. The 
      current study aims to look into any association between rs11646054 variant in 
      SLC5A2 gene and the anti-diabetic efficacy and safety of empagliflozin. METHODS: 
      14 T2DM who failed to respond to previous treatments, empagliflozin 10 mg was 
      added for 6 months. Genotyping of the rs11646054 variant of SLC5A2 gene was 
      performed by polymerase chain reaction (PCR) followed by Sanger sequencing. 
      RESULTS: Although hemoglobin A1c (HbA1c) and low-density lipoprotein (LDL) were 
      not significantly different, but the mean fasting blood sugar (FBS), 2-h post 
      prandial (2hpp), albumin-to-creatinine ratio (ACR), and total cholesterol (TC) 
      were significantly decreased after 6 months empagliflozin treatment. There was a 
      significant difference in the mean final reductions in FBS level among genotypes. 
      It's important to mention that those who were GG homozygotes had a tendency to 
      have more decrements. CONCLUSIONS: The study results indicate that effects of 
      variation in SLC5A2 (rs11646054) on the clinical efficacy of empagliflozin were 
      negligible.
CI  - (c) Springer Nature Switzerland AG 2021.
FAU - Jamalizadeh, Mahdieh
AU  - Jamalizadeh M
AUID- ORCID: 0000-0001-7743-1624
AD  - Personalized Medicine Research Center, Endocrinology and Metabolism Clinical 
      Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. GRID: 
      grid.411705.6. ISNI: 0000 0001 0166 0922
AD  - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran. GRID: 
      grid.411705.6. ISNI: 0000 0001 0166 0922
FAU - Hasanzad, Mandana
AU  - Hasanzad M
AUID- ORCID: 0000-0002-0538-1135
AD  - Personalized Medicine Research Center, Endocrinology and Metabolism Clinical 
      Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. GRID: 
      grid.411705.6. ISNI: 0000 0001 0166 0922
AD  - Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad 
      University, Tehran, Iran. GRID: grid.411463.5. ISNI: 0000 0001 0706 2472
FAU - Sarhangi, Negar
AU  - Sarhangi N
AUID- ORCID: 0000-0003-2385-7333
AD  - Personalized Medicine Research Center, Endocrinology and Metabolism Clinical 
      Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. GRID: 
      grid.411705.6. ISNI: 0000 0001 0166 0922
FAU - Sharifi, Farshad
AU  - Sharifi F
AUID- ORCID: 0000-0002-2035-6587
AD  - Elderly Health Research Center, Endocrinology and Metabolism Population Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran. GRID: 
      grid.411705.6. ISNI: 0000 0001 0166 0922
FAU - Nasli-Esfahani, Ensieh
AU  - Nasli-Esfahani E
AUID- ORCID: 0000-0001-6334-5469
AD  - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran. GRID: 
      grid.411705.6. ISNI: 0000 0001 0166 0922
FAU - Larijani, Bagher
AU  - Larijani B
AUID- ORCID: 0000-0001-5386-7597
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences, 
      No.10-Jalal-e-Ale-Ahmad Street, Chamran Highway, 1411713119 Tehran, Iran. GRID: 
      grid.411705.6. ISNI: 0000 0001 0166 0922
LA  - eng
PT  - Journal Article
DEP - 20210810
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC8630276
OTO - NOTNLM
OT  - Empagliflozin
OT  - SGLT2 inhibitor
OT  - SLC5A2
OT  - Type 2 diabetes mellitus
OT  - rs11646054
COIS- Competing of interestThere are no conflicts of interest declared by the authors.
EDAT- 2021/12/14 06:00
MHDA- 2021/12/14 06:01
PMCR- 2022/08/10
CRDT- 2021/12/13 18:07
PHST- 2021/06/21 00:00 [received]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/12/13 18:07 [entrez]
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2021/12/14 06:01 [medline]
PHST- 2022/08/10 00:00 [pmc-release]
AID - 874 [pii]
AID - 10.1007/s40200-021-00874-4 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2021 Aug 10;20(2):1407-1413. doi: 
      10.1007/s40200-021-00874-4. eCollection 2021 Dec.